Evidence map›Paper›PMID 39829639›Full record

ArticleOpen forum infectious diseases2025

Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis.

Barbara D Alexander, Melissa Johnson, Mark Bresnik, Vamshi Ruthwik Anupindi, Lia Pizzicato, Mitchell DeKoven, Belinda Lovelace, Craig I Coleman

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Barbara D AlexanderInfectious Diseases Division, Duke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0001-5868-0529
Melissa JohnsonInfectious Diseases Division, Duke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0002-6606-9460
Mark BresnikF2G, Inc., Princeton, New Jersey, USA.
Vamshi Ruthwik AnupindiIQVIA, Falls Church, Virginia, USA.ORCID https://orcid.org/0000-0002-0385-8657
Lia PizzicatoIQVIA, Falls Church, Virginia, USA.
Mitchell DeKovenIQVIA, Falls Church, Virginia, USA.ORCID https://orcid.org/0000-0001-9346-6202
Belinda LovelaceF2G, Inc., Princeton, New Jersey, USA.
Craig I ColemanDepartment of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, Connecticut, USA.ORCID https://orcid.org/0000-0003-4868-7158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Early antifungal initiation in invasive aspergillosis (IA) is recommended. Changing antifungals occurs for a myriad of reasons but associated costs are unclear. Methods: US claims data for adults admitted for IA were identified from 10/1/2015 to 11/30/2022. Patients were stratified by those who did and did not change antifungal therapy. Adjusted all-cause healthcare utilization and costs/patient during index hospitalization and at 1, 6, and 12-months after the index date between the cohorts that did and did not change antifungal therapy were compared. Results: Among 1,192 IA patients, 707 (59.3%) changed their initial antifungal therapy over follow-up. The index hospital length of stay was longer (Δ = 6 days, Conclusions: Changing antifungals was associated with longer hospital stays and costs and higher all-cause costs over 12-months.

Indexed as

amphotericin Bantifungal agentsaspergillosisazolecosts and costs analysistherapy change

Identifiers

PMID39829639
PMCPMC11739793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.